Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Tuesday, March 27, 2012

Medical News:Data Confirm PARP Inhibitor (Olaparib) Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today

Medical News:Data Confirm PARP Inhibitor Slows Ovarian Ca - in Meeting Coverage, SGO from MedPage Today


Action Points

Note that this randomized, placebo controlled study demonstrates that olaparib, an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor, significantly improved progression-free survival but not overall survival, in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer.

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.